ライフサイエンスコーパス: noncancerous

1 trained to classify patches as cancerous or noncancerous.

2 tically increased in human HCC compared with noncancerous adjacent tissues.

3 ir gene-metabolites associations compared to noncancerous adjacent tissues.

4 sion: This is the first direct evidence that noncancerous, adult human livers harbor several types of

5 as a positive control (PC) and binds to both noncancerous and cancer cells through the HIV-derived TA

6 t PTEN signaling regulates infection of both noncancerous and cancerous cells by multiple intracellul

7 However, molecular circadian rhythms in noncancerous and cancerous human breast tissues and thei

8 ere also found in epithelial and mesenchymal noncancerous and cancerous tissues and cell lines.

9 differential levels of cell proliferation in noncancerous and cancerous tissues correlated with a str

10 to be present in all cells tested in vitro, noncancerous and cancerous, including patient-derived tu

11 s varying in abundance between cancerous and noncancerous areas in various human tissues were selecte

12 ected complexes were also tested against the noncancerous ARPE-19 (retinal pigment epithelial cells)

13 h which to discriminate prostate cancer from noncancerous benign disease depend on the type of benign

14 Compared with noncancerous biliary epithelial cells, the expression of

15 ncreased levels of miR-26a compared with the noncancerous biliary epithelial cells.

16 ancer cell lines but were less active in the noncancerous BJ-hTERT cells.

17 erous (LNCaP, C4-B, DU145, and PC-3) but not noncancerous (BPH-1) prostate epithelial cells by down-r

18 eak signal from tumor cells hidden among the noncancerous brain tissue of the peritumoral edema.

19 ific to cancer and do not generally occur in noncancerous breast disease.

20 .003] and activated natural killer cells in noncancerous breast tissue of Black women [beta, 0.11 (9

21 Noncancerous breast tissue was collected from women who

22 For noncancerous breast tissue, inflammatory, epithelial-mes

23 consists of epithelial cultures derived from noncancerous breast tissue, treated with the chemical ca

24 aneous differentiation between cancerous and noncancerous breast tissues utilizing metabolic and lipi

25 ic diagnosis was cancerous, precancerous, or noncancerous but had the potential for local destruction

26 lines (HeLa, A2780, and A2780cisR) and on a noncancerous cell line (HFL-1).

27 ortantly, significantly less active toward a noncancerous cell line (MRC-5).

28 t cancer), DU145 (prostate cancer), or Vero (noncancerous cell line).

29 n assessed and compared with L1210 and human noncancerous cell lines.

30 drug-resistant colon cancer cell lines over noncancerous cell lines.

31 atives, which were screened in cancerous and noncancerous cell lines.

32 ore sensitive to these molecules compared to noncancerous cell lines.

33 rk uncovers 771 interactions from cancer and noncancerous cell states, including WT and mutant protei

34 e RNA-DNA interactions mapped in two normal, noncancerous cell types [using iMARGI, an enhanced versi

35 Among these noncancerous cell types, monocytes (microglia and macrop

36 os, but they were not significantly toxic to noncancerous cells (HEK293).

37 cancerous cells (MCF-7 and MDA-MB-435) over noncancerous cells (HUVECs and MCF-10A).

38 l line) with negligible cytotoxicity against noncancerous cells (MCF-10A and peripheral blood mononuc

39 presence of a vast excess of the respective noncancerous cells [NIH 3T3 cells, human embryonic kidne

40 and was about 40 times less toxic toward the noncancerous cells and 4-fold more toxic toward the Dox

41 rmation capture experiment demonstrated that noncancerous cells and breast cancer cells exhibit diffe

42 HO-3867 exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in

43 a high selectivity for cancerous cells over noncancerous cells and were found to be active in drug r

44 of cancer cells was more sensitive over the noncancerous cells by these FONPs due to overexpression

45 ast cancer cells, with minimal uptake by the noncancerous cells compared to the linear peptide with t

46 onversely, when Protrudin was overexpressed, noncancerous cells developed prominent invadopodia-like

47 s p53 transcription and selectively protects noncancerous cells from p53-dependent apoptosis.

48 However, the cytotoxicity toward noncancerous cells having typical membrane compositions,

49 asion-promoting factors and can also rely on noncancerous cells in the tumor microenvironment as an a

50 K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.

51 In contrast, TFEB silencing in noncancerous cells is associated with replication stress

52 e expressions of glycans in cancerous versus noncancerous cells of the same origin, this approach has

53 C-POC uptake is significantly lowered in the noncancerous cells populating the tumor microenvironment

54 Noncancerous cells preferentially obtain fatty acids fro

55 Noncancerous cells remained unaffected during this regim

56 Tumours are surrounded by a host of noncancerous cells that fulfil both supportive and suppr

57 eld-the tumor microenvironment including all noncancerous cells within the tumor and surrounding tiss

58 ons, whether this methylation also occurs in noncancerous cells, and whether these epigenetic events

59 rkably, no relevant effects were detected on noncancerous cells, denoting the importance of deliverin

60 rostate cancer (PCa) specimens than adjacent noncancerous cells.

61 lated protein, MR1, while remaining inert to noncancerous cells.

62 oliferation, without affecting the growth of noncancerous cells.

63 emotherapy is the lack of selectivity toward noncancerous cells.

64 nanofilaments were nontoxic to cancerous and noncancerous cells.

65 ous cells while maintaining redox balance in noncancerous cells.

66 nes (lung, breast, pancreatic, prostate) and noncancerous cells.

67 t cancer cell lines, but minimal toxicity in noncancerous cells.

68 expression in human and murine cancerous and noncancerous cells.

69 matic hypermutation in cancers as well as in noncancerous cells.

70 tion and accessibility between cancerous and noncancerous cells.

71 tosis and autophagy, with minimal effects on noncancerous cells.

72 mor activity, while being less toxic against noncancerous cells.

73 er cells by apoptosis, with little effect on noncancerous cells.

74 mon liability of cancer drugs is toxicity to noncancerous cells.

75 ubsets to discriminate between cancerous and noncancerous cells.

76 uman cells have also been discriminated from noncancerous cells.

77 d the cancerous cells than the corresponding noncancerous cells.

78 s electronegative relative to the surface of noncancerous cells.

79 sma of cancer patients admixed with DNA from noncancerous cells.

80 and human papillomavirus "low-risk" types in noncancerous clinical outcomes.

81 In noncancerous colon tissues from patients with ulcerative

82 mechanism, E(2) influences the physiology of noncancerous colonocytes, resulting in fewer preneoplast

83 focused on evaluating the effects of E(2) in noncancerous colonocytes.

84 Here we examined tissues from noncancerous colons of ulcerative colitis patients to de

85 platform to redefine cancer drugs for use in noncancerous conditions.

86 ause following hysterectomy/oophorectomy for noncancerous conditions; it is also commonly prescribed

87 lted in increased cancerous cell death while noncancerous control cells were unaffected.

88 stologically confirmed breast cancer and 406 noncancerous controls with information on both serum PCB

89 lectivity against cancer cells while sparing noncancerous counterparts.

90 ity at 99% specificity and for subjects with noncancerous cysts, 30% sensitivity at 99% specificity.

91 On four real cancerous or noncancerous datasets, insights from SCIPAC help interpr

92 tectomy slides were annotated for cancer and noncancerous disease and coregistered to MR imaging with

93 Computer-identified features for each of the noncancerous disease categories (eg, benign prostatic hy

94 play complex roles in the transition from a noncancerous disease state to cancer in the gastrointest

95 of cancer and have been implicated in other, noncancerous diseases and aging.

96 apies are being considered for treating rare noncancerous diseases like pulmonary hypertension (PH),

97 cology, a synopsis of preliminary reports in noncancerous diseases, and a discussion of relevant emer

98 e are also correlated to the pathogenesis of noncancerous diseases, such as skin pathologies and COVI

99 which are qualitative and do not account for noncancerous elements within the tumor microenvironment.

100 ocarcinoma and adjacent (normal or abnormal) noncancerous endometrium underwent successful clonal ana

101 eration of MCF-7 cells but not MCF-10 cells (noncancerous epithelial cells).

102 onfidently distinguish between cancerous and noncancerous epithelial prostate cells in vitro.

103 colorectal adenocarcinoma cell line and from noncancerous fetal lung tissue.

104 city against human breast adenocarcinoma and noncancerous fibroblasts, identifying a novel class of F

105 ypes (AUC = 0.70) compared with grouping all noncancerous findings together (AUC = 0.62).

106 e, radiation exposure, and detection rate of noncancerous findings.

107 nhance cell growth and increase migration of noncancerous HEK cells; indeed, both properties were alm

108 ancer cells but show reduced cytotoxicity to noncancerous HEK293 cells with the more extended system

109 average selectivity index of 6.2 compared to noncancerous HEK293 cells.

110 uld not be identified from the corresponding noncancerous hepatic tissues.

111 r-null livers showed strong Nrf2 activity in noncancerous hepatocytes, there was no correlation betwe

112 erived from transcriptional responses in the noncancerous host tissues as well as the developing tumo

113 enocarcinoma breast cell lines compared with noncancerous human breast epithelial cells.

114 ls were more sensitive to Ru-NAP compared to noncancerous human embryonic kidney (HEK293 cells) when

115 cancer, cervical cancer cell lines, and the noncancerous human fibroblast cell line.

116 ably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic ef

117 altering the proliferation of immortalized, noncancerous human peripheral airway cells.

118 symbiotic interactions between GBM cells and noncancerous immune cells (e.g., myeloid cells and T cel

119 uracy in discriminating cancer patients from noncancerous individuals via linear discriminant analysi

120 st 3-fold in all of the tumors compared with noncancerous kidney and contained known WT-related genes

121 lines (SK-MEL, KB, BT-549, SK-OV-3) and two noncancerous kidney cell lines (LLC-PK1 and Vero).

122 is and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing

123 the highest expression change compared with noncancerous kidney was topoisomerase IIalpha.

124 The noncancerous lesions are equally distributed proximally

125 the incidence, latency, and histotype of two noncancerous lesions, hyperplastic alveolar nodules (ana

126 2 of 254 (87%) nodules larger than 6 mm were noncancerous lesions.

127 ues, including 77 pairs of HCCs and matching noncancerous liver and 22 normal livers, were analyzed f

128 theoretical possibility of injuring adjacent noncancerous liver cells, thereby restricting the liver'

129 onnexin-based and pannexin-based channels in noncancerous liver disease.

130 rom an arterial source while the majority of noncancerous liver is supplied by the portal vein.

131 tohepatitis patients as well as the adjacent noncancerous liver tissues of a subset of HCC patients w

132 Host DNA extracted from fragments of noncancerous liver, collected during surgical resection

133 lite markers in 81 HCCs and 77 corresponding noncancerous livers as a measure of CIN.

134 Noncancerous livers demonstrated increased methylation i

135 ere significantly higher in the HCCs than in noncancerous livers in 18 of the 21 loci (P values range

136 lines, while no cytotoxicity was observed in noncancerous lung fibroblasts, IMR-90.

137 eration sequencing of BRMS1 on matched human noncancerous lung tissue and non-small cell lung cancer

138 ns from 1,251 samples of normal and diseased noncancerous lung tissue RNA sequencing with paired whol

139 es in freshly resected cancerous and matched noncancerous lung tissues from nonsmall cell lung cancer

140 s in human NSCLC tissues, in contrast to the noncancerous lung tissues from the same patient, which s

141 Here, we show that the noncancerous mammary cell line HMT-3522 S1, when allowed

142 r their effects on breast cancer (SKBr3) and noncancerous mammary cells (HB2).

143 a transgenic mice acquire both cancerous and noncancerous mammary lesions.

144 Our approach reveals that interacting noncancerous MCF10A cells can be described by repulsion

145 TFEB silencing in MDA-MB-231 and noncancerous MCF10A cells impaired progression through t

146 -MB-231) binding compared to when exposed to noncancerous (MCF10A and HUVEC) cells.

147 syngeneic mouse teratoma model derived from noncancerous mouse embryonic stem cells and conducted a

148 have stable populations of cancer-prone, but noncancerous, mutant cells awaiting further genetic hits

149 ion was reduced in NPC tissues compared with noncancerous nasopharyngeal epithelial tissues.

150 ortened after each round of cell division in noncancerous normal cells, while the activation of telom

151 ns of interest (POIs) in cancer cells versus noncancerous normal cells.

152 ns of interest (POIs) in cancer cells versus noncancerous normal cells.

153 ized to undergo either RF or IRE ablation of noncancerous normal liver.

154 ing a panel of human cancer cell lines and a noncancerous one, evidencing promising potency of 1, 7,

155 nsporter was relatively nontoxic to cells of noncancerous origin.

156 somes but was also observed with exosomes of noncancerous origin.

157 ctively respiring Saos2 and HOS OS cells and noncancerous osteoblastic hFOB cells.

158 ne NuTu-19 and for cell toxicity against the noncancerous ovarian tissue cell line OVepi.

159 ; 50 with chronic pancreatitis; and 125 with noncancerous pancreatic cysts).

160 of PDAC samples versus healthy controls and noncancerous pancreatic disease.

161 and overexpressed KDM3A in HPNE cells (human noncancerous pancreatic ductal cell line); we evaluated

162 fected and noninfected PDAC cells but not in noncancerous pancreatic epithelial cells, suggesting aut

163 SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by cocultur

164 nity for the application of CAR T therapy to noncancerous pathologies.

165 ancies, focusing on cancer but also covering noncancerous physiology, and the therapeutic potential o

166 ) synthase, resulting in Gb(3) expression in noncancerous polarized epithelial cells lacking endogeno

167 igh levels in cancer cells relative to their noncancerous precursors.

168 as been expanded to study both cancerous and noncancerous prostate cells.

169 tant induced anchorage-independent growth of noncancerous prostate epithelial cells (RWPE-1).

170 iting enzyme) was expressed in cancerous and noncancerous prostate glands.

171 ine and other biofluids, but also cancer and noncancerous prostate tissue, has resulted in new biomar

172 ress higher levels of this truncated AR than noncancerous prostate tissue.

173 methylation in 30 DNA samples isolated from noncancerous prostate tissue.

174 compared to samples of hormone-naive PCa and noncancerous prostate tissue.

175 xin family, gene expression profiles from 21 noncancerous prostate tissues, 16 clinically localized P

176 of miR-299-3p in prostate tumors compared to noncancerous prostate tissues.

177 ples examined and detectable in only 2 of 52 noncancerous prostate tissues.

178 cers, 91 metastatic prostate cancers, and 25 noncancerous prostate tissues.

179 ted between the clinically localized PCa and noncancerous prostate tissues.

180 BKV is present at a much lower frequency in noncancerous prostates.

181 pression in cancerous LNCaP cells but not in noncancerous PWR-1E and RWPE-1 cells (all human prostate

182 st cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells.

183 f selected metabolites between cancerous and noncancerous regions of the kidney tissue and also betwe

184 f selected metabolites between cancerous and noncancerous regions of the kidney tissue.

185 tissue samples containing both cancerous and noncancerous regions, obtained from three patients with

186 ion of miR-155 and suppression of lncTCL6 in noncancerous renal cell HK2 induced tumorigenic characte

187 this study, we stably expressed E6 and E7 in noncancerous RPE1 cells and analyzed the specific mitoti

188 es with their power in predicting cancer vs. noncancerous samples.

189 In noncancerous settings, neutrophils are first responders

190 basal cell or squamous cell carcinomas from noncancerous skin abnormalities, such as actinic keratos

191 tinguishable from germline variants or other noncancerous somatic mutations.

192 RNA expression profiles of 482 cancerous and noncancerous specimens from radical resection of 241 pat

193 RNA-sequencing approach to gastric tumor and noncancerous specimens, generating 680 million informati

194 In the early noncancerous stages, well-amplified integration sites we

195 ns arising during DNA replication in normal, noncancerous stem cells.

196 s, but little is known about how they affect noncancerous stromal cells within the tumor microenviron

197 ing placebo and probiotic consumption and 10 noncancerous subjects using Real-Time PCR.

198 Clustering also separated cancerous from noncancerous tissue and cell lines from in vivo tissues

199 gests a high rate of premalignant changes in noncancerous tissue before the formation of a solitary t

200 ompositions that enhance cancer vs. adjacent noncancerous tissue classification across five different

201 analyzed the apoptotic profile for tumor and noncancerous tissue for each biopsy specimen using IHC.

202 pairs of DNA samples from colon cancers and noncancerous tissue with topoisomerase I and then amplif

203 samples revealed that, compared with that in noncancerous tissue, L1 expression is specifically enhan

204 of NUAK1 and NUAK2 in cancerous compared to noncancerous tissue.

205 ncy, age-associated somatic TP53 mutation in noncancerous tissue.

206 primary and metastatic tumors compared with noncancerous tissue.

207 tected mouse GLUT6 protein expression in any noncancerous tissue; therefore, in this study, we invest

208 ines and 47 primary tumors and corresponding noncancerous tissues by a methylation-specific PCR.

209 RY2, CKI, CLOCK, and BMAL1) of cancerous and noncancerous tissues from 29 GC patients were investigat

210 lines, nine matched CRC tissues and adjacent noncancerous tissues using reverse transcription (RT)-PC

211 TVM expression in tumors and noncancerous tissues was assessed by qRT-PCR and was pro

212 h blood samples, breast tumors, and adjacent noncancerous tissues were collected from women with brea

213 oma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spec

214 In corresponding noncancerous tissues, hypermethylation in RAR-beta and F

215 Compared with noncancerous tissues, PC expression was greatly enhanced

216 f miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of

217 detected in HCC tumor tissues compared with noncancerous tissues.

218 ata from 31 hepatocellular carcinomas and 19 noncancerous tissues.

219 ss genes is less likely to cause toxicity to noncancerous tissues.

220 he mean ADC values for malignant lesions and noncancerous tissues.

221 d samples, 48 breast tumors, and 41 adjacent noncancerous tissues.

222 compared by immunoblotting with the adjacent noncancerous tissues.

223 escalated doses may also increase injury to noncancerous tissues.

224 iver tumor tissues compared with the matched noncancerous tissues.

225 tations in the nontumorous colonic tissue in noncancerous UC cases indicate genetic damage from expos

226 frequency of specific p53 mutated alleles in noncancerous UC colon tissue may confer susceptibility t

227 hways fails to enhance the classification of noncancerous vs. cancerous tissues and the prediction of